Key clinical point: Comorbidities were common among children and young adults with severe COVID-19 disease; more severe cases showed elevated inflammatory markers.
Major finding: Patients with severe disease had significantly higher levels of C-reactive protein, procalcitonin, peak interleukin 6, ferritin, and D-dimer, compared with those with less severe disease
Study details: The data come from a retrospective study of 50 children and young adults aged 21 years and younger who tested positive for COVID-19 between March 1 and April 15, 2020.
Disclosures: The study received no outside funding. Dr. Zachariah had no financial conflicts to disclose. Two coauthors reported ties with various pharmaceutical companies and organizations.
Zachariah P et al. JAMA Pediatr. 2020 June 3. doi: 10.1001/jamapediatrics.2020.2430.